A novel and improved method of differentiating infection from inflammation

EP4767066A1Pending Publication Date: 2026-07-01ABACUSLABS LTD
0 Cites 0 Cited by

Patent Information

Application Number
EP2024771892
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-08-23
Filing Date
2024-08-23
Publication Date
2026-07-01

AI Technical Summary

Technical Problem

Current biomarkers, such as Serum Amyloid A (SAA) and C-reactive protein (CRP), fail to accurately differentiate between infectious and inflammatory processes, leading to inappropriate antibiotic use and misdiagnosis in patients with chronic inflammatory conditions.

Method used

The method involves measuring and differentiating between SAA1 and SAA2 isoforms using isoform-specific antibodies, allowing for the quantitative determination and differentiation of these biomarkers in whole blood, serum, or plasma. This is achieved through platforms like Enzyme-linked Immunosorbent Assay (ELISA), dipstick assays, or lateral flow assays.

Benefits of technology

This approach enables accurate differentiation between inflammation and infection, allowing for targeted treatment with anti-inflammatory therapeutics or antibiotics, thereby reducing unnecessary antibiotic use and improving patient outcomes.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A method of determining a health status of an individual, the method comprising the steps of assaying a biological sample from the individual for the positive expression of SAA1 and / or SAA2, and wherein the positive expression of the SAA1 and / or SAA2 above or below a threshold expression level in a control sample correlates with the health status of the individual.
Need to check novelty before this filing date? Find Prior Art